Cargando…
EMA401: an old antagonist of the AT2R for a new indication in neuropathic pain
EMA401 is an old molecule, synthesized by Parke-Davis in the last century and characterized at that time as an AT2R antagonist. Professor Maree Smith and her group from the University of Queensland (Australia) patented the drug and many related derivatives and other compounds with high affinity for...
Autores principales: | Keppel Hesselink, Jan M, Schatman, Michael E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325092/ https://www.ncbi.nlm.nih.gov/pubmed/28255254 http://dx.doi.org/10.2147/JPR.S128520 |
Ejemplares similares
-
Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT(2)R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies
por: Anand, Uma, et al.
Publicado: (2015) -
Rediscovery of old drugs: the forgotten case of dermorphin for postoperative pain and palliation
por: Hesselink, Jan M Keppel, et al.
Publicado: (2018) -
Ethical justification of single-blind and double-blind placebo-controlled response tests in neuropathic pain and N-of-1 treatment paradigm in clinical settings
por: Keppel Hesselink, Jan M, et al.
Publicado: (2019) -
Topical phenytoin for the treatment of neuropathic pain
por: Kopsky, David J, et al.
Publicado: (2017) -
“But that is your opinion”: the dark side of postmodern pain medicine creating a postmodern patient autonomy
por: Hesselink, Jan M Keppel, et al.
Publicado: (2018)